Trials / Terminated
TerminatedNCT00820105
ADX10059 Migraine Prevention Study
A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging, Multicentre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 for the Prevention of Migraine
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- Sponsor
- Addex Pharma S.A. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of ADX10059 to prevent migraine attacks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADX10059 | oral administration |
| DRUG | ADX10059 | Oral administration |
| DRUG | ADX10059 | Oral administration |
| DRUG | ADX10059 Matching Placebo | Oral administration |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2010-01-01
- First posted
- 2009-01-09
- Last updated
- 2009-12-24
Locations
31 sites across 5 countries: Austria, Belgium, France, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT00820105. Inclusion in this directory is not an endorsement.